DOCSLIB.ORG

List of European Pharmacopoeia Reference Standards

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of European Pharmacopoeia Reference Standards List of European Pharmacopoeia Reference Standards Effective from 2021/9/29 Order Reference Standard Batch Quantity Sale Information Monograph Storage Shipping Shipment Price Code n° per vial Unit group with DGD Y0001552 Abacavir for peak identification CRS 1 10 mg 1 2589 +5°C+/-3°C A1A 79 € Y0001551 Abacavir for system suitability CRS 1 10 mg 1 2589 +5°C+/-3°C A1A 79 € Y0001561 Abacavir sulfate CRS 1 20 mg 1 2589 +5°C+/-3°C A1A 79 € Y0002199 Acamprosate calcium CRS 1 80 mg 1 See leaflet 1585 +5°C+/-3°C A1A 79 € Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 This reference standard was officially withdrawn from monograph 1585 L 79 € 01/2017:1585 on 01/01/2021 and replaced by Y0002199 Acamprosate calcium. The reference will however remain available for sale for a further 6 months (subject to stock availability), i.e. until 01/07/2021. The reference will remain visible in the catalogue until 01/01/2022. ; Batch 1 is valid until 1 January 2022 Y0000116 Acamprosate impurity A CRS 2 110 mg 1 3-aminopropane-1-sulfonic acid (homotaurine) 1585 +5°C+/-3°C A1A 79 € Y0000500 Acarbose CRS 3 100 mg 1 See leaflet 2089 +5°C+/-3°C A1A 79 € Y0000354 Acarbose for identification CRS 1 10 mg 1 2089 +5°C+/-3°C A1A 79 € Y0000427 Acarbose for peak identification CRS 4 20 mg 1 2089 +5°C+/-3°C A1A 79 € A0040000 Acebutolol hydrochloride CRS 1 50 mg 1 0871 +5°C+/-3°C A1A 79 € Y0000359 Acebutolol impurity B CRS 2 10 mg 1 N-[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] 0871 +5°C+/-3°C A1A 79 € propoxy]phenyl]acetamide (diacetolol) Y0000127 Acebutolol impurity C CRS 2 20 mg 1 See Leaflet; N-(3-acetyl-4-hydroxyphenyl)butanamide ; Batch 1 is 0871 +5°C+/-3°C A1A 79 € valid until 31 October 2021 Y0000128 Acebutolol impurity I CRS 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2- 0871 +5°C+/-3°C A1A 79 € hydroxypropoxy]phenyl]butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 L 79 € Y0000085 Aceclofenac impurity F CRS 4 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate 1281 +5°C+/-3°C A1A 79 € (benzyl ester of aceclofenac) Y0000086 Aceclofenac impurity H CRS 2 10 mg 1 [[[[[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetyl] 1281 +5°C+/-3°C A1A 79 € oxy]acetyl]oxy]acetic acid (diacetic aceclofenac) Y0001094 Aceclofenac for peak identification CRS 2 10 mg 1 1281 +5°C+/-3°C A1A 79 € Y0001915 Aceclofenac impurity I CRS 1 15 mg 1 1281 +5°C+/-3°C A1A 79 € Y0000810 Acemetacin CRS 1 100 mg 1 1686 +5°C+/-3°C A1A 79 € Y0000811 Acemetacin impurity A CRS 1 10 mg 1 4-chlorobenzoic acid 1686 +5°C+/-3°C A1A 79 € Y0000842 Acemetacin impurity mixture CRS 1 0.06 mg 1 1686 +5°C+/-3°C A1A 79 € A0070000 Acesulfame potassium CRS 2 50 mg 1 1282 +5°C+/-3°C A1A 79 € A0070020 Acesulfame potassium impurity B CRS 5 15 mg 1 see leaflet; 5-chloro-6-methyl-1,2,3-oxathiazin-4(3§)-one 2,2- 1282 +5°C+/-3°C A1A 79 € dioxide ; Batch 4 is valid until 31 October 2020 A0100000 Acetazolamide CRS 1 100 mg 1 0454 +5°C+/-3°C A1A 79 € Y0001084 Acetazolamide for system suitability CRS 3 0.007 mg 1 Batch 2 is valid until 31 March 2021 0454 +5°C+/-3°C A1A 79 € Y0000002 Acetylcholine chloride CRS 2 50 mg 1 1485,1971 -20°C C1A 79 € +/-5°C For extra charges, please see terms and conditions. © Council of Europe, all rights reserved 2021 1 DGD : Dangerous Goods Declaration. List of European Pharmacopoeia Reference Standards Effective from 2021/9/29 Order Reference Standard Batch Quantity Sale Information Monograph Storage Shipping Shipment Price Code n° per vial Unit group with DGD A0150000 Acetylcysteine CRS 4 50 mg 1 Batch 3 is valid until 31 January 2021 0967 +5°C+/-3°C A1A 79 € A0152000 Acetylcysteine impurity C CRS 12 10 mg 1 (2R,2'R)-3,3'-disulfanediylbis[2-(acetylamino)propanoic acid] 0967 +5°C+/-3°C A1A 79 € (N,N'-diacetyl-L-cystine) ; Batch 11 is valid until 31 July 2021 A0153000 Acetylcysteine impurity D CRS 7 10 mg 1 (2R)-2-(acetylamino)-3-(acetylsulfanyl)propanoic acid (N,S- 0967 +5°C+/-3°C A1A 79 € diacetyl-L-cysteine) Y0000565 ß-Acetyldigoxin CRS 2 50 mg 1 See leaflet C÷–HÿÿOŒ— 2168 +5°C+/-3°C A1A 79 € Y0000642 ß-acetyldigoxin for peak identification CRS 1 10 mg 1 2168 +5°C+/-3°C A1A 79 € A0200000 Acetylsalicylic acid CRS 5 10 mg 1 0309 +5°C+/-3°C A1A 79 € Y0001460 Acetylsalicylic acid for peak identification CRS 5 10.3 mg 1 0309 +5°C+/-3°C A1A 79 € Y0001462 Acetylsulfadiazine CRS 2 0.002 mg 1 0294 +5°C+/-3°C A1A 79 € A0208000 N-Acetyltryptophan CRS 3 125 mg 1 Batch 2 is valid until 30 September 2020 1383 +5°C+/-3°C A1A 79 € A0202000 N-Acetyltyrosine CRS 1 200 mg 1 1384 +5°C+/-3°C A1A 79 € Y0000693 Acholeplasma laidlawii BRP 1 1 ml 1 20607 -80°C D1A 120 € +/-10°C Y0002053 Achyranthes bidentata root dry extract for 1 10 mg 1 2999 -20°C C1a 79 € system suitability HRS +/-5°C A0220000 Aciclovir CRS 3 75 mg 1 0968 +5°C+/-3°C A1A 79 € Y0001954 N-acyl-phosphatidylethanolamine from Soya 1 40 mg 1 2316 -20°C C1a 79 € bean CRS +/-5°C New Y0002242 Aciclovir for impurity C identification CRS 2 0.3 mg 1 Batch 1 is valid until 31 December 2021 0968 +5°C+/-3°C A1A 79 € Y0002244 Aciclovir for impurity G identification CRS 1 0.004 mg 1 0968 +5°C+/-3°C A1A 79 € Y0001271 Aciclovir for peak identification 1 CRS 6 0.3 mg 1 This reference standard was officially withdrawn from monograph 0968 +5°C+/-3°C A1A 79 € 01/2014:0968 on 01/04/2021 and replaced by Aciclovir for impurity C identification Y0002242. The reference will however remain available for sale for a further 6 months (subject to stock availability), i.e. until 01/10/2021. The reference will remain visible in the catalogue until 01/04/2022. ; Batch 6 is valid until 2 April 2022 Y0001269 Aciclovir for peak identification 2 CRS 6 0.004 mg 1 This reference standard was officially withdrawn from monograph 0968 +5°C+/-3°C A1A 79 € 01/2014:0968 on 01/04/2021 and replaced by Aciclovir for impurity G identification Y0002244. The reference will however remain available for sale for a further 6 months (subject to stock availability), i.e. until 01/10/2021. The reference will remain visible in the catalogue until 01/04/2022. ; Batch 5 is valid until 31 January 2021 Batch 6 is valid until 2 April 2022 For extra charges, please see terms and conditions. © Council of Europe, all rights reserved 2021 2 DGD : Dangerous Goods Declaration. List of European Pharmacopoeia Reference Standards Effective from 2021/9/29 Order Reference Standard Batch Quantity Sale Information Monograph Storage Shipping Shipment Price Code n° per vial Unit group with DGD Y0001264 Aciclovir for system suitability CRS 2 20 mg 1 This reference standard was officially withdrawn from monograph 0968 +5°C+/-3°C A1A 79 € 01/2014:0968 on 01/04/2021 and replaced by Aciclovir for system suitability A Y0002245. The reference will however remain available for sale for a further 6 months (subject to stock availability), i.e. until 01/10/2021. The reference will remain visible in the catalogue until 01/04/2022. ; Batch 1 is valid until 30 September 2021 Batch 2 is valid until 1 April 2022 Y0002245 Aciclovir for system suitability A CRS 1 20 mg 1 0968 +5°C+/-3°C A1A 79 € A0225000 Acitretin CRS 3 100 mg 1 See leaflet CœŒHœÿO– 1385 +5°C+/-3°C B1A 79 € Y0001987 Acitretin for impurity A identification CRS 1 5 mg 1 1385 +5°C+/-3°C B1a 79 € Y0001464 Actaea racemosa dry extract for system 1 1200 mg 1 2069 -20°C C1A 79 € suitability HRS +/-5°C Y0001543 Actaea racemosa for assay CRS 1 300 mg 1 See leaflet C÷œHÿ—NOŒÿ; Monoammonium glycyrrhizate 2069 +5°C+/-3°C A1A 79 € Y0001463 Actaea racemosa HRS 1 1200 mg 1 2069 +5°C+/-3°C A1A 79 € Y0001121 Adapalene CRS 2 100 mg 1 See leaflet Cœ‡Hœ‡O– 2445 +5°C+/-3°C A1A 79 € Y0001120 Adapalene impurity C CRS 4 10 mg 1 1-(2-methoxyphenyl)tricyclo[3.3.1.1]decane 2445 +5°C+/-3°C A1A 79 € Y0001119 Adapalene for peak identification CRS 2 2.02 mg 1 2445 +5°C+/-3°C A1A 79 € A0230000 Adenine CRS 3 50 mg 1 0800 +5°C+/-3°C A1A 79 € A0230200 Adenosine CRS 1 50 mg 1 1486 +5°C+/-3°C A1A 79 € Y0000110 Adipic acid CRS 1 50 mg 1 1586 +5°C+/-3°C A1A 79 € Y0000882 Adrenaline CRS 1 5 mg 1 Synonym (adrenaline): Epinephrine 2303 +5°C+/-3°C A1A 79 € Y0002246 Adrenaline impurity F CRS 1 0.008 mg 1 Synonym (adrenaline): Epinephrine 2303 +5°C+/-3°C A1A 79 € Y0000740 Adrenaline impurity mixture CRS 4 0.005 mg 1 Synonym (adrenaline): Epinephrine 0254,2303 +5°C+/-3°C A1A 79 € A0300000 Adrenaline tartrate CRS 6 100 mg 1 Synonym (adrenaline): Epinephrine 0254 +5°C+/-3°C A1A 79 € Y0000707 Adrenaline tartrate with impurity A CRS 1 15 mg 1 Synonym (adrenaline): Epinephrine 0254 +5°C+/-3°C A1A 79 € Y0000883 Adrenaline with impurity F CRS 2 0.008 mg 1 Synonym (adrenaline): Epinephrine 2303 +5°C+/-3°C A1A 79 € This reference standard was officially withdrawn from monograph 07/2008:2303 on 01/01/2021.
Load more

Recommended publications
  • Trihydroxyisoflavone Improves Skin Barrier Function Impaired by E
    www.nature.com/scientificreports OPEN A novel mineralocorticoid receptor antagonist, 7,3’,4’‑trihydroxyisofavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids Hanil Lee1,5, Eun‑Jeong Choi2,5, Eun Jung Kim1, Eui Dong Son2, Hyoung‑June Kim2, Won‑Seok Park2, Young‑Gyu Kang2, Kyong‑Oh Shin3, Kyungho Park3, Jin‑Chul Kim4, Su‑Nam Kim4 & Eung Ho Choi1* Excess glucocorticoids (GCs) with either endogenous or exogenous origins deteriorate skin barrier function. GCs bind to mineralocorticoid and GC receptors (MRs and GRs) in normal human epidermal keratinocytes (NHEKs). Inappropriate MR activation by GCs mediates various GC‑induced cutaneous adverse events. We examined whether MR antagonists can ameliorate GC‑mediated skin barrier dysfunction in NHEKs, reconstructed human epidermis (RHE), and subjects under psychological stress (PS). In a preliminary clinical investigation, topical MR antagonists improved skin barrier function in topical GC‑treated subjects. In NHEKs, cortisol induced nuclear translocation of GR and MR, and GR and MR antagonists inhibited cortisol‑induced reductions of keratinocyte diferentiation. We identifed 7,3’,4’‑trihydroxyisofavone (7,3’,4’‑THIF) as a novel compound that inhibits MR transcriptional activity by screening 30 cosmetic compounds. 7,3’,4’‑THIF ameliorated the cortisol efect which decreases keratinocyte diferentiation in NHEKs and RHE. In a clinical study on PS subjects, 7,3’,4’‑ THIF (0.1%)‑containing cream improved skin barrier function, including skin surface pH, barrier recovery rate, and stratum corneum lipids. In conclusion, skin barrier dysfunction owing to excess GC is mediated by MR and GR; thus, it could be prevented by treatment with MR antagonists. Therefore, topical MR antagonists are a promising therapeutic option for skin barrier dysfunction after topical GC treatment or PS.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al
    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Report Name:Ukraine's Mrls for Veterinary Drugs
    Voluntary Report – Voluntary - Public Distribution Date: November 05,2020 Report Number: UP2020-0051 Report Name: Ukraine's MRLs for Veterinary Drugs Country: Ukraine Post: Kyiv Report Category: FAIRS Subject Report Prepared By: Oleksandr Tarassevych Approved By: Robin Gray Report Highlights: Ukraine adopted several maximum residue levels (MRLs) for veterinary drugs, coccidiostats and histomonostats in food products of animal origin. Ukraine also adopted a list of drugs residues that are not allowed in food products. THIS REPORT CONTAINS ASSESSMENTS OF COMMODITY AND TRADE ISSUES MADE BY USDA STAFF AND NOT NECESSARILY STATEMENTS OF OFFICIAL U.S. GOVERNMENT POLICY The Office of Agricultural Affairs of USDA/Foreign Agricultural Service in Kyiv, Ukraine prepared this report for U.S. exporters of domestic food and agricultural products. While every possible care was taken in the preparation of this report, information provided may not be completely accurate either because policies have changed since the time this report was written, or because clear and consistent information about these policies was not available. It is highly recommended U.S. exporters verify the full set of import requirements with their foreign customers, who are normally best equipped to research such matters with local authorities, before any goods are shipped. This FAIRS Subject Report accompanies other reports on Maximum, Residue Limits established by Ukraine in 2020. Related reports could be found under the following links: 1.) Ukraine's MRLs for Microbiological Contaminants_Kyiv_Ukraine_04-27-2020 2.) Ukraine's MRLs for Certain Contaminants_Kyiv_Ukraine_03-06-2020 Food Products of animal origin and/or ingredients of animal origin are not permitted in the Ukrainian market if they contain certain veterinary drugs residues in excess of the maximum residue levels established in Tables 1 and 2.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Flonase Sensimist Allergy Relief (Fluticasone Furoate)
    Flonase® Sensimist™ Allergy Relief (fluticasone furoate) – Rx-to-OTC Approval • On February 8, 2017, GlaxoSmithKline Consumer Healthcare announced the launch of Flonase Sensimist Allergy Relief (fluticasone furoate) nasal spray, as an over the counter (OTC) treatment to temporarily relieve symptoms of hay fever or other upper respiratory allergies: nasal congestion; runny nose; sneezing; itchy nose; and itchy, watery eyes (in ages 12 years and older). — Flonase Sensimist Allergy Relief contains 27.5 mcg/spray of fluticasone furoate. — Flonase Sensimist Allergy Relief should not be used in children less than 2 years of age. • Previously, fluticasone furoate was only available by prescription as Veramyst®. Veramyst is no longer commercially available. • Fluticasone is also available OTC as brand (Flonase® Allergy Relief, Children’s Flonase® Allergy Relief) and generic products containing 50 mcg/spray of fluticasone propionate. — These products share the same indications as Flonase Sensimist Allergy Relief, but are not intended for children under 4 years of age. • Prescription fluticasone propionate nasal spray (50 mcg/spray) is available generically and indicated for the management of the nasal symptoms of perennial non-allergic rhinitis in adult and pediatric patients aged 4 years and older. • Warnings for Flonase Sensimist Allergy Relief state the following: — Do not use: in children under 2 years of age, to treat asthma, if there is an injury or surgery to the nose that is not fully healed, or if an allergic reaction to Flonase Sensimist Allergy Relief or any of its ingredients has occurred. — Ask a doctor prior to use if the patient has or had glaucoma or cataracts.
    [Show full text]
  • Difference Between Patient-Reported Side Effects of Ciclesonide Versus fluticasone Propionate
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Respiratory Medicine (2010) 104, 1825e1833 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Difference between patient-reported side effects of ciclesonide versus fluticasone propionate Thys van der Molen a, Juliet M. Foster a,b, Manfred Caeser c,e, Thomas Mu¨ller c, Dirkje S. Postma d,* a Department of General Practice, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands b Woolcock Institute of Medical Research, 431 Glebe Point Rd, Glebe NSW 2037, Sydney, Australia c Nycomed GmbH, Byk-Gulden-Straße 2, 78467 Konstanz, Konstanz, Germany d Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands Received 18 January 2010; accepted 26 May 2010 Available online 2 July 2010 KEYWORDS Summary Adverse events; Rationale: Patient-reported outcomes provide new insights into the dynamics of asthma Inhaled corticosteroid management. Further to asthma control and quality of life, self-reported side effects of treat- questionnaire; ment can be assessed with the validated Inhaled Corticosteroid Questionnaire (ICQ). ICQ; Objectives: To compare patient-reported side effects between the inhaled corticosteroids Patient-reported ciclesonide and fluticasone propionate. outcomes Methods: Patients with moderate or moderate-to-severe asthma, pre-treated with a constant dose and type of medication, were randomized in three separate studies: 1) once daily cicle- sonide 320 mg(n Z 234) or twice daily fluticasone propionate 200 mg(n Z 240); 2) twice daily ciclesonide 320 mg(n Z 255) or twice daily fluticasone propionate 375 mg(n Z 273); and 3) twice daily ciclesonide 320 mg(n Z 259) or twice daily fluticasone propionate 500 mg (n Z 244).
    [Show full text]
  • Journal of Pharmaceutical and Biomedical Analysis Stability Of
    Journal of Pharmaceutical and Biomedical Analysis 49 (2009) 519–524 Contents lists available at ScienceDirect Journal of Pharmaceutical and Biomedical Analysis journal homepage: www.elsevier.com/locate/jpba Short communication Stability of selected chlorinated thiazide diuretics K. Deventer a,∗, G. Baele b, P. Van Eenoo a, O.J. Pozo a, F.T. Delbeke a a DoCoLab, UGent, Department of Clinical Chemistry, Microbiology and Immunology, Technologiepark 30, B-9052 Zwijnaarde, Belgium b Department of Applied Mathematics and Computer Science, Krijgslaan 281, S9, B-9000 Gent, Belgium article info abstract Article history: In sports, diuretics are used for two main reasons: to flush previously taken prohibited substances with Received 6 August 2008 forced diuresis and in sports where weight classes are involved to achieve acute weight loss. A com- Received in revised form 5 November 2008 mon property observed for thiazides is hydrolysis in aqueous media resulting in the formation of the Accepted 6 November 2008 degradation product aminobenzenedisulphonamide. This degradation product can be observed for sev- Available online 13 November 2008 eral thiazides. Because there is limited information regarding the effect of pH, temperature and light on the stability of thiazides, these parameters were investigated for chlorothiaizide, hydrochlorothiazide Keywords: and altizide. For all three compounds the degradation product could be detected after incubation at pH Doping ◦ Urine 9.5 for 48 h at 60 C. At lower pH and temperature the degradation product could not be detected for all Diuretics compounds. When samples were exposed to UV-light altizide and hydrochlorothiazide were photode- Thiazides graded to chlorothiazide. When the degradation rate between the different compounds was compared Sports for a given temperature and pH, altizide is the most unstable compound.
    [Show full text]